Click Here for 5% Off Your First Aladdin Purchase!

Nicotinic acid - 99%, high purity , CAS No.59-67-6, Agonist of HCA 2 receptor

  • Moligand™
  • ≥99%
Item Number
N103652
Grouped product items
SKUSizeAvailabilityPrice Qty
N103652-5g
5g
In stock
$9.90
N103652-25g
25g
In stock
$15.90
N103652-100g
100g
In stock
$29.90
N103652-500g
500g
In stock
$49.90

Antidyslipidemic agent

View related series
HCA2 receptor Agonist

Basic Description

Synonymsnicotinic acid|niacin|59-67-6|Pyridine-3-carboxylic acid|3-pyridinecarboxylic acid|vitamin B3|3-Carboxypyridine|wampocap|Niaspan|Acidum nicotinicum|nicolar|Apelagrin|Pellagrin|Akotin|Daskil|Efacin|Pelonin|Linic|nicamin|nicobid|nicocap|Enduracin|Nicodelmin
Specifications & PurityMoligand™, ≥99%
Biochemical and Physiological MechanismsDecreases hepatic production of very-low density lipoproteins and apolipoprotein B.Antidyslipidemic. Increases high-density- and lowers low-density lipoproteins. Putative ligand for the HM74A receptor.
Shipped InNormal
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of HCA 2 receptor
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

A major chemical component of coenzymes NAD+ and NADP+

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD4 Tchem D(4) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ERBB2 Tclin Receptor tyrosine-protein kinase erbB-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GABRA1 Tclin Gamma-aminobutyric acid receptor subunit alpha-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ELANE Tclin Neutrophil elastase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HMGCR Tclin 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SIGMAR1 Tclin Sigma non-opioid intracellular receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CA2 Tclin Carbonic anhydrase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD3 Tclin D(3) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

XDH Tclin Xanthine dehydrogenase/oxidase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM3 Tclin Muscarinic acetylcholine receptor M3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM4 Tclin Muscarinic acetylcholine receptor M4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2B Tclin Alpha-2B adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2A Tclin 5-hydroxytryptamine receptor 2A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA2A Tclin Adenosine receptor A2a 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA1A Tclin Alpha-1A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAOA Tclin Amine oxidase [flavin-containing] A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1B1 Tclin Aldose reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

APP Tclin Amyloid-beta A4 protein 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA1 Tclin Adenosine receptor A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR1A Tclin 5-hydroxytryptamine receptor 1A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR3A Tclin 5-hydroxytryptamine receptor 3A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR6 Tchem 5-hydroxytryptamine receptor 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRA Tclin Endothelin-1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRB Tclin Endothelin receptor type B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRD1 Tclin Delta-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRK1 Tclin Kappa-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS2 Tchem Nitric oxide synthase, inducible 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TACR1 Tclin Substance-P receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS1 Tchem Nitric oxide synthase, brain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Pubchem Sid488179574
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488179574
IUPAC Name pyridine-3-carboxylic acid
INCHI InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChi Key PVNIIMVLHYAWGP-UHFFFAOYSA-N
Canonical SMILES C1=CC(=CN=C1)C(=O)O
Isomeric SMILES C1=CC(=CN=C1)C(=O)O
RTECS QT0525000
Alternate CAS 59-67-6,99148-57-9 (tosylate)
PubChem CID 938
NSC Number 169454
MeSH Entry Terms 3 Pyridinecarboxylic Acid;3-Pyridinecarboxylic Acid;Aluminum Salt, Niacin;Enduracin;Hydrochloride, Niacin;Induracin;Lithium Nicotinate;Niacin;Niacin Aluminum Salt;Niacin Ammonium Salt;Niacin Calcium Salt;Niacin Cobalt (2+) Salt;Niacin Copper (2+) Salt;Nia
Molecular Weight 123.11
Beilstein 109591

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

31 results found

Lot NumberCertificate TypeDateItem
H2429484Certificate of AnalysisSep 04, 2024 N103652
H2429483Certificate of AnalysisSep 04, 2024 N103652
H2429482Certificate of AnalysisSep 04, 2024 N103652
D2412473Certificate of AnalysisMay 06, 2024 N103652
D2412474Certificate of AnalysisMay 06, 2024 N103652
D2412471Certificate of AnalysisMay 06, 2024 N103652
D2412469Certificate of AnalysisMay 06, 2024 N103652
D2412467Certificate of AnalysisMay 06, 2024 N103652
E2410188Certificate of AnalysisMar 18, 2024 N103652
E2410202Certificate of AnalysisMar 18, 2024 N103652
G2321822Certificate of AnalysisJul 27, 2023 N103652
G2321856Certificate of AnalysisJul 26, 2023 N103652
G2321870Certificate of AnalysisJul 26, 2023 N103652
H2231744Certificate of AnalysisMay 11, 2023 N103652
H2231743Certificate of AnalysisMay 11, 2023 N103652
H2231742Certificate of AnalysisMay 11, 2023 N103652
H2231569Certificate of AnalysisMay 11, 2023 N103652
H2231741Certificate of AnalysisMay 11, 2023 N103652
D2321318Certificate of AnalysisMay 04, 2023 N103652
C2308516Certificate of AnalysisMar 15, 2023 N103652
C2308448Certificate of AnalysisMar 15, 2023 N103652
C2308437Certificate of AnalysisMar 15, 2023 N103652
C2308406Certificate of AnalysisMar 15, 2023 N103652
C2308403Certificate of AnalysisMar 13, 2023 N103652
C2308438Certificate of AnalysisMar 13, 2023 N103652
C2308421Certificate of AnalysisMar 13, 2023 N103652
B2303895Certificate of AnalysisFeb 07, 2023 N103652
F2222047Certificate of AnalysisJun 28, 2022 N103652
F2222046Certificate of AnalysisJun 28, 2022 N103652
F2222027Certificate of AnalysisDec 08, 2021 N103652
L2101527Certificate of AnalysisDec 08, 2021 N103652

more

Chemical and Physical Properties

SolubilitySoluble in water (15 g/l at 20 °C), hot alcohol, alkali hydroxides, propylene glycol, water (150 g/l at 100 °C), ethanol (12.5 g/l at 25 °C), DMSO (25 mg/ml), methanol, carbonates, and water (15 g/l at 20 °C). Insoluble in diethyl ether.
SensitivityLight sensitive.
Flash Point(°C)193°C
Melt Point(°C)238°C

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H319:Causes serious eye irritation

H412:Harmful to aquatic life with long lasting effects

Precautionary Statements

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P273:Avoid release to the environment.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P501:Dispose of contents/container to ...

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P337+P317:If eye irritation persists: Get medical help.

RTECS QT0525000
Merck Index 6525

Related Documents

References

1. Boatman PD, Schrader TO, Kasem M, Johnson BR, Skinner PJ, Jung JK, Xu J, Cherrier MC, Webb PJ, Semple G et al..  (2010)  Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a)..  Bioorg Med Chem Lett,  20  (9): (2797-800).  [PMID:20363624]
2. Shen HC, Taggart AK, Wilsie LC, Waters MG, Hammond ML, Tata JR, Colletti SL.  (2008)  Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A..  Bioorg Med Chem Lett,  18  (18): (4948-51).  [PMID:18752940]
3. Hanson J, Gille A, Offermanns S.  (2012)  Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin..  Pharmacol Ther,  136  (1): (1-7).  [PMID:22743741]
4. Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, Moss SM, Paoletta S, Kiselev E, Lu W et al..  (2014)  Structure of the human P2Y12 receptor in complex with an antithrombotic drug..  Nature,  509  (7498): (115-8).  [PMID:24670650]
5. Zhang J, Zhang K, Gao ZG, Paoletta S, Zhang D, Han GW, Li T, Ma L, Zhang W, Müller CE et al..  (2014)  Agonist-bound structure of the human P2Y12 receptor..  Nature,  509  (7498): (119-22).  [PMID:24784220]
6. J E Mrochek,R L Jolley,D S Young,W J Turner.  (1976-11-01)  Metabolic response of humans to ingestion of nicotinic acid and nicotinamide..  Clinical chemistry,  22  ((11)): (1821-1827).  [PMID:135660]
7. H Hertle,M Kiese,G Renner.  (1979-01-01)  Absorption in rats, dogs, pigs, and humans of nicotinic acid after oral administration of phosphatidyl inositol pentanicotinate hydrochloride (PIN)..  Arzneimittel-Forschung,  29  ((1)): (114-116).  [PMID:582105]
8. N Hengen,V Seiberth,M Hengen.  (1978-10-01)  High-performance liquid-chromatographic determination of free nicotinic acid and its metabolite, nicotinuric acid, in plasma and urine..  Clinical chemistry,  24  ((10)): (1740-1743).  [PMID:699281]
9. M R Stratford,M F Dennis,P Hoskin,H Phillips,R J Hodgkiss,A Rojas.  (1996-07-01)  Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring..  British journal of cancer,  74  ((1)): (16-21).  [PMID:8679452]
10. A Viola,F Nicoli,B Denis,S Confort-Gouny,Y Le Fur,J-P Ranjeva,P Viout,P J Cozzone.  (2004-09-02)  High cerebral scyllo-inositol: a new marker of brain metabolism disturbances induced by chronic alcoholism..  Magma (New York, N.Y.),  17  ((1)): (47-61).  [PMID:15340856]
11. Nicholas B Pike.  (2005-12-03)  Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid..  The Journal of clinical investigation,  115  ((12)): (3400-3403).  [PMID:16322787]
12. L R G Nieminen,K K Makino,N Mehta,M Virkkunen,H Y Kim,J R Hibbeln.  (2006-09-09)  Relationship between omega-3 fatty acids and plasma neuroactive steroids in alcoholism, depression and controls..  Prostaglandins, leukotrienes, and essential fatty acids,  75  ((4-5)): (309-314).  [PMID:16959481]
13. Tawfik Gharbaoui,Philip J Skinner,Young-Jun Shin,Claudia Averbuj,Jae-Kyu Jung,Benjamin R Johnson,Tracy Duong,Marc Decaire,Jane Uy,Martin C Cherrier,Peter J Webb,Susan Y Tamura,Ning Zou,Nathalie Rodriguez,P Douglas Boatman,Carleton R Sage,Andrew Lindstrom,Jerry Xu,Thomas O Schrader,Brian M Smith,Ruoping Chen,Jeremy G Richman,Daniel T Connolly,Steven L Colletti,James R Tata,Graeme Semple.  (2007-06-26)  Agonist lead identification for the high affinity niacin receptor GPR109a..  Bioorganic & medicinal chemistry letters,  17  ((17)): (4914-4919).  [PMID:17588745]
14. Katrina L Bogan,Charles Brenner.  (2008-04-24)  Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition..  Annual review of nutrition,  28  (115-130).  [PMID:18429699]
15. Subharekha Raghavan,G Scott Tria,Hong C Shen,Fa-Xiang Ding,Andrew K Taggart,Ning Ren,Larrisa C Wilsie,Mihajlo L Krsmanovic,Tom G Holt,Michael S Wolff,M Gerard Waters,Milton L Hammond,James R Tata,Steven L Colletti.  (2008-05-15)  Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists..  Bioorganic & medicinal chemistry letters,  18  ((11)): (3163-3167).  [PMID:18477506]
16. H E Bays,D J Rader.  (2008-12-05)  Does nicotinic acid (niacin) lower blood pressure?.  International journal of clinical practice,  63  ((1)): (151-159).  [PMID:19054161]
17. Jason E Imbriglio,Sookhee Chang,Rui Liang,Subharekha Raghavan,Darby Schmidt,Abby Smenton,Scott Tria,Thomas O Schrader,Jae-Kyu Jung,Craig Esser,Andrew K P Taggart,Kang Cheng,Ester Carballo-Jane,M Gerard Waters,James R Tata,Steven L Colletti.  (2009-03-25)  GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a..  Bioorganic & medicinal chemistry letters,  19  ((8)): (2121-2124).  [PMID:19307116]
18. Paul Martres.  (2009-06-13)  HM74a agonists: will they be the new generation of nicotinic acid?.  Current topics in medicinal chemistry,  ((5)): (428-435).  [PMID:19519459]
19. Caroline M Perry.  (2009-08-15)  Extended-release niacin (nicotinic acid)/laropiprant..  Drugs,  69  ((12)): (1665-1679).  [PMID:19678716]
20. Heinz Drexel.  (2009-08-18)  Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?.  Fundamental & clinical pharmacology,  23  ((6)): (687-692).  [PMID:19682084]
21. Sean Ekins,Antony J Williams,Jinghai J Xu.  (2010-09-17)  A predictive ligand-based Bayesian model for human drug-induced liver injury..  Drug metabolism and disposition: the biological fate of chemicals,  38  ((12)): (2302-2308).  [PMID:20843939]
22. Hans F N Kvitvang,Trygve Andreassen,Tomas Adam,Silas G Villas-Bôas,Per Bruheim.  (2011-03-11)  Highly sensitive GC/MS/MS method for quantitation of amino and nonamino organic acids..  Analytical chemistry,  83  ((7)): (2705-2711).  [PMID:21388201]
23. Arie Markel.  (2011-08-04)  The resurgence of niacin: from nicotinic acid to niaspan/laropiprant..  The Israel Medical Association journal : IMAJ,  13  ((6)): (368-374).  [PMID:21809737]
24. Rachael Hartman,Taylor Defelice,Julia Tzu,Shane Meehan,Miguel Sanchez.  (2011-10-28)  Acanthosis nigricans in the setting of niacin therapy..  Dermatology online journal,  17  ((10)): (11-11).  [PMID:22031637]
25. James M McKenney.  (2012-02-09)  Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review..  Postgraduate medicine,  124  ((1)): (7-20).  [PMID:22314110]
26. Anastazia Kei,Moses S Elisaf.  (2012-05-09)  Nicotinic acid: clinical considerations..  Expert opinion on drug safety,  11  ((4)): (551-564).  [PMID:22564238]
27. Tai-Heng Chen,Clement Mtika.  (2012-11-02)  The peeling dermatitis with a peculiar demarcation..  The American journal of the medical sciences,  346  ((5)): (421-421).  [PMID:23114198]
28. Robert Ringseis,Susann Rosenbaum,Denise K Gessner,Lea Herges,Johanna F Kubens,Frank-Christoph Mooren,Karsten Krüger,Klaus Eder.  (2012-12-21)  Supplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibers..  The Journal of nutrition,  143  ((2)): (125-131).  [PMID:23256146]
29. U Julius,S Fischer.  (2013-01-30)  Nicotinic acid as a lipid-modifying drug--a review..  Atherosclerosis. Supplements,  14  ((1)): (7-13).  [PMID:23357134]
30. Wanda C Lakey,Nicole Greyshock,John R Guyton.  (2013-02-19)  Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants..  Journal of clinical lipidology,  ((2)): (178-181).  [PMID:23415439]
31. Antonio F Santidrian,Akemi Matsuno-Yagi,Melissa Ritland,Byoung B Seo,Sarah E LeBoeuf,Laurie J Gay,Takao Yagi,Brunhilde Felding-Habermann.  (2013-02-22)  Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression..  The Journal of clinical investigation,  123  ((3)): (1068-1081).  [PMID:23426180]
32. Angela Pirillo,Giuseppe Danilo Norata,Alberico Luigi Catapano.  (2013-02-23)  High-density lipoprotein subfractions--what the clinicians need to know..  Cardiology,  124  ((2)): (116-125).  [PMID:23428644]
33. .  (2013-03-08)  Drugs for hypertriglyceridemia..  The Medical letter on drugs and therapeutics,  55  ((1411)): (17-19).  [PMID:23467119]
34. Tom Noff,Jerald Insel.  (2013-04-06)  Energy drinks and the unwanted buzz: a case report..  Maryland medicine : MM : a publication of MEDCHI, the Maryland State Medical Society,  13  ((4)): (28-29).  [PMID:23556369]
35. Baiba K Gillard,Joe L Raya,Raul Ruiz-Esponda,Dinakar Iyer,Ivonne Coraza,Ashok Balasubramanyam,Henry J Pownall.  (2013-05-04)  Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function..  Arteriosclerosis, thrombosis, and vascular biology,  33  ((7)): (1714-1721).  [PMID:23640486]
36. N Nakajima,M Ueda,N Higashi,Y Katayama.  (2013-05-07)  Erythromelalgia associated with Clitocybe acromelalga intoxication..  Clinical toxicology (Philadelphia, Pa.),  51  ((5)): (451-454).  [PMID:23641936]
37. Koon K Teo,Larry B Goldstein,Bernard R Chaitman,Shannon Grant,William S Weintraub,David C Anderson,Cathy A Sila,Salvador Cruz-Flores,Robert J Padley,William J Kostuk,William E Boden.  (2013-07-25)  Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial..  Stroke,  44  ((10)): (2688-2693).  [PMID:23881958]
38. Pieter-Jan De Kam,Wen-Lin Luo,Larissa Wenning,Lisa Ratcliffe,Christine McCrary Sisk,Jane Royalty,Waldemar Radziszewski,John A Wagner,Eseng Lai.  (2013-11-12)  The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin..  Platelets,  25  ((7)): (480-487).  [PMID:24206527]
39. Matthew D W Piper,Eric Blanc,Ricardo Leitão-Gonçalves,Mingyao Yang,Xiaoli He,Nancy J Linford,Matthew P Hoddinott,Corinna Hopfen,George A Soultoukis,Christine Niemeyer,Fiona Kerr,Scott D Pletcher,Carlos Ribeiro,Linda Partridge.  (2013-11-19)  A holidic medium for Drosophila melanogaster..  Nature methods,  11  ((1)): (100-105).  [PMID:24240321]
40. Kimberly A Gudzune,Anne K Monroe,Ritu Sharma,Padmini D Ranasinghe,Yohalakshmi Chelladurai,Karen A Robinson.  (2014-02-12)  Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review..  Annals of internal medicine,  160  ((7)): (468-476).  [PMID:24514899]
41. Hans-Michael Wolff,Irsan,Kalliopi Dodou.  (2014-03-07)  Investigations on the viscoelastic performance of pressure sensitive adhesives in drug-in-adhesive type transdermal films..  Pharmaceutical research,  31  ((8)): (2186-2202).  [PMID:24599801]
42. Donald M Lloyd-Jones.  (2014-07-12)  Niacin and HDL cholesterol--time to face facts..  The New England journal of medicine,  371  ((3)): (271-273).  [PMID:25014692]
43. Todd J Anderson,William E Boden,Patrice Desvigne-Nickens,Jerome L Fleg,Moti L Kashyap,Ruth McBride,Jeffrey L Probstfield.  (2014-07-12)  Safety profile of extended-release niacin in the AIM-HIGH trial..  The New England journal of medicine,  371  ((3)): (288-290).  [PMID:25014706]
44. Michael McCarthy.  (2014-07-25)  Niacin fails to reduce vascular events in large randomised trial..  BMJ (Clinical research ed.),  349  (g4774-g4774).  [PMID:25055803]
45. Mack Moyo,Stephen O Amoo,Adeyemi O Aremu,Jiří Gruz,Michaela Subrtová,Karel Doležal,Johannes Van Staden.  (2014-09-16)  Plant regeneration and biochemical accumulation of hydroxybenzoic and hydroxycinnamic acid derivatives in Hypoxis hemerocallidea organ and callus cultures..  Plant science : an international journal of experimental plant biology,  227  (157-164).  [PMID:25219317]
46. Anja Veronovski,Gabrijela Tkalec,Željko Knez,Zoran Novak.  (2014-09-27)  Characterisation of biodegradable pectin aerogels and their potential use as drug carriers..  Carbohydrate polymers,  113  (272-278).  [PMID:25256485]
47. K Maráková,J Piestanský,E Havránek,P Mikus.  (2014-10-03)  Simultaneous analysis of vitamins B in pharmaceuticals and dietary supplements by capillary electrophoresis hyphenated with triple quadrupole mass spectrometry..  Die Pharmazie,  69  ((9)): (663-668).  [PMID:25272936]
48. Christopher M Rembold.  (2014-11-13)  Niacin for reduction of cardiovascular risk..  The New England journal of medicine,  371  ((20)): (1940-1941).  [PMID:25390749]
49. Miao Hu,Brian Tomlinson.  (2014-11-13)  Niacin for reduction of cardiovascular risk..  The New England journal of medicine,  371  ((20)): (1941-1942).  [PMID:25390751]
50. Amit V Khera,Arman Qamar,Muredach P Reilly,Richard L Dunbar,Daniel J Rader.  (2014-11-30)  Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia..  The American journal of cardiology,  115  ((2)): (178-182).  [PMID:25432415]
51. Vladimir Tolstikov,Alexander Nikolayev,Sucai Dong,Genshi Zhao,Ming-Shang Kuo.  (2014-12-09)  Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells..  PloS one,  ((12)): (e114019-e114019).  [PMID:25486521]
52. Won Seok Yang,Hyun Woo Kim,Joo Mi Lee,Nam Jeong Han,Mee Jeong Lee,Su-Kil Park.  (2015-01-04)  1,25-dihydroxyvitamin D3 causes ADAM10-dependent ectodomain shedding of tumor necrosis factor receptor 1 in vascular smooth muscle cells..  Molecular pharmacology,  87  ((3)): (533-542).  [PMID:25556238]
53. Umi Fahmida,Otte Santika,Risatianti Kolopaking,Elaine Ferguson.  (2015-02-03)  Complementary feeding recommendations based on locally available foods in Indonesia..  Food and nutrition bulletin,  35  ((4 Suppl)): (S174-S179).  [PMID:25639135]
54. Rohini Sidhu,Hui Jiang,Nicole Y Farhat,Nuria Carrillo-Carrasco,Myra Woolery,Elizabeth Ottinger,Forbes D Porter,Jean E Schaffer,Daniel S Ory,Xuntian Jiang.  (2015-04-14)  A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid..  Journal of lipid research,  56  ((6)): (1222-1233).  [PMID:25866316]
55. Mónica Acevedo,Paola Varleta,Verónica Kramer,Giovanna Valentino,Teresa Quiroga,Carolina Prieto,Jacqueline Para.  (2015-06-20)  Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor..  International journal of endocrinology,  2015  (934681-934681).  [PMID:26089902]
56. M Verdú,A Bach,M Devant.  (2015-06-27)  Effect of concentrate feeder design on performance, eating and animal behavior, welfare, ruminal health, and carcass quality in Holstein bulls fed high-concentrate diets..  Journal of animal science,  93  ((6)): (3018-3033).  [PMID:26115288]
57. Shuai Yang,Xitao Li,Nasui Wang,Guoshu Yin,Shuhua Ma,Yucai Fu,Chiju Wei,Yongsong Chen,Wencan Xu.  (2015-06-28)  GPR109A Expression in the Murine Min6 Pancreatic Beta Cell Line, and Its Relation with Glucose Metabolism and Inflammation..  Annals of clinical and laboratory science,  45  ((3)): (315-322).  [PMID:26116596]
58. Karine Meisser Redeuil,Karin Longet,Sylvie Bénet,Caroline Munari,Esther Campos-Giménez.  (2015-11-03)  Simultaneous quantification of 21 water soluble vitamin circulating forms in human plasma by liquid chromatography-mass spectrometry..  Journal of chromatography. A,  1422  (89-98).  [PMID:26522745]
59. D L Cooper,J A Carmical,P C Panus,S Harirforoosh.  (2015-11-05)  Formulation and in vitro evaluation of niacin-loaded nanoparticles to reduce prostaglandin mediated vasodilatory flushing..  European review for medical and pharmacological sciences,  19  ((20)): (3977-3988).  [PMID:26531288]
60. Mahesh S Desai,Anna M Seekatz,Nicole M Koropatkin,Nobuhiko Kamada,Christina A Hickey,Mathis Wolter,Nicholas A Pudlo,Sho Kitamoto,Nicolas Terrapon,Arnaud Muller,Vincent B Young,Bernard Henrissat,Paul Wilmes,Thaddeus S Stappenbeck,Gabriel Núñez,Eric C Martens.  (2016-11-20)  A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility..  Cell,  167  ((5)): (1339-1353).  [PMID:27863247]
61. Patricia L Baker,Gregory S Orf,Zahid Khan,Levi Espinoza,Sabrina Leung,Kimberly Kevershan,Kevin E Redding.  (2019-08-04)  A Molecular Biology Tool Kit for the Phototrophic Firmicute Heliobacterium modesticaldum..  Applied and environmental microbiology,  85  ((19)):   [PMID:31375483]
62. Dominic A Colosimo,Jeffrey A Kohn,Peter M Luo,Frank J Piscotta,Sun M Han,Amanda J Pickard,Arka Rao,Justin R Cross,Louis J Cohen,Sean F Brady.  (2019-08-06)  Mapping Interactions of Microbial Metabolites with Human G-Protein-Coupled Receptors..  Cell host & microbe,  26  ((2)): (273-282).  [PMID:31378678]
63. Shokouh Ahmadi,Shaohua Wang,Ravinder Nagpal,Rabina Mainali,Sabihe Soleimanian-Zad,Dalane Kitzman,Hariom Yadav.  (2019-08-20)  An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota..  Journal of visualized experiments : JoVE,      [PMID:31424444]
64. Federica Gaudino,Ilaria Manfredonia,Antonella Managò,Valentina Audrito,Nadia Raffaelli,Tiziana Vaisitti,Silvia Deaglio.  (2019-08-29)  Subcellular Characterization of Nicotinamide Adenine Dinucleotide Biosynthesis in Metastatic Melanoma by Using Organelle-Specific Biosensors..  Antioxidants & redox signaling,  31  ((15)): (1150-1165).  [PMID:31456414]
65. Ana O Quintana-Escobar,Geovanny I Nic-Can,Rosa María Galaz Avalos,Víctor M Loyola-Vargas,Elsa Gongora-Castillo.  (2019-10-23)  Transcriptome analysis of the induction of somatic embryogenesis in Coffea canephora and the participation of ARF and Aux/IAA genes..  PeerJ,  (e7752-e7752).  [PMID:31637116]
66. Miguel A Uc-Chuc,Cleyre Pérez-Hernández,Rosa M Galaz-Ávalos,Ligia Brito-Argaez,Víctor Aguilar-Hernández,Víctor M Loyola-Vargas.  (2020-07-09)  YUCCA-Mediated Biosynthesis of the Auxin IAA Is Required during the Somatic Embryogenic Induction Process in Coffea canephora..  International journal of molecular sciences,  21  ((13)):   [PMID:32635392]
67. Joonhoon Kim,Samuel T Coradetti,Young-Mo Kim,Yuqian Gao,Junko Yaegashi,Jeremy D Zucker,Nathalie Munoz,Erika M Zink,Kristin E Burnum-Johnson,Scott E Baker,Blake A Simmons,Jeffrey M Skerker,John M Gladden,Jon K Magnuson.  (2021-02-16)  Multi-Omics Driven Metabolic Network Reconstruction and Analysis of Lignocellulosic Carbon Utilization in Rhodosporidium toruloides..  Frontiers in bioengineering and biotechnology,  (612832-612832).  [PMID:33585414]
68. Paniz Izadi,Marten Niklas Gey,Nicolas Schlüter,Uwe Schröder.  (2021-08-03)  Bidirectional electroactive microbial biofilms and the role of biogenic sulfur in charge storage and release..  iScience,  24  ((8)): (102822-102822).  [PMID:34337365]
69. W H Sutherland,P W Larking,E R Nye.  (1976-10-01)  Modification of nicotinic acid and prostaglandin E1 antilipolytic action in vitro..  Atherosclerosis,  25  ((1)): (45-53).  [PMID:186078]
70. H Chart,H R Smith,R M La Ragione,M J Woodward.  (2000-12-21)  An investigation into the pathogenic properties of Escherichia coli strains BLR, BL21, DH5alpha and EQ1..  Journal of applied microbiology,  89  ((6)): (1048-1058).  [PMID:11123478]
71. Fabrizio Montecucco,Alessandra Quercioli,Franco Dallegri,Giorgio Luciano Viviani,François Mach.  (2010-10-13)  New evidence for nicotinic acid treatment to reduce atherosclerosis..  Expert review of cardiovascular therapy,  ((10)): (1457-1467).  [PMID:20936932]
72. Insug Kang,Sang-Wook Kim,Jang H Youn.  (2011-08-06)  Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug..  The Journal of clinical endocrinology and metabolism,  96  ((10)): (3048-3055).  [PMID:21816780]
73. Willibald Hochholzer,David D Berg,Robert P Giugliano.  (2011-09-07)  The facts behind niacin..  Therapeutic advances in cardiovascular disease,  ((5)): (227-240).  [PMID:21893559]
74. Douglas MacKay,John Hathcock,Erminia Guarneri.  (2012-06-01)  Niacin: chemical forms, bioavailability, and health effects..  Nutrition reviews,  70  ((6)): (357-366).  [PMID:22646128]
75. Amit V Khera,Parin J Patel,Muredach P Reilly,Daniel J Rader.  (2013-08-13)  The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality..  Journal of the American College of Cardiology,  62  ((20)): (1909-1910).  [PMID:23933538]
76. Zhichao Liu,Qiang Shi,Don Ding,Reagan Kelly,Hong Fang,Weida Tong.  (2011-12-24)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)..  PLoS computational biology,  ((12)): (e1002310-e1002310).  [PMID:22194678]

Solution Calculators